Unveil Pharma
Venture capitalBoston · Pre-Seed–Series A · 1 people tracked
Investment thesis
UNVEILpharma invests in early-stage biotech companies with curated technologies that have a clear path to exit within five years. The firm leverages world-class deal flow from academic institutions like Harvard and MIT, and provides operational value through deep expertise in drug development and commercialization.
Source: firm website, verified Aug 6, 2026.
Team · 1 people
from public directories
Frequently asked questions
- What stage does Unveil Pharma invest at?
- Unveil Pharma invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Unveil Pharma focus on?
- Unveil Pharma focuses on Biotech.
- Where is Unveil Pharma located?
- Unveil Pharma is headquartered in Boston, US.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Felicis Ventures is a venture capital firm that backs founders primarily at the Seed and Series A stages, frequently leading or co-leading rounds. It operates with a founder-first approach, including a founder pledge and voting commitments.
Fly Ventures is an early-stage venture firm that backs founders at the zero-to-one stage, with portfolio companies going on to raise substantial follow-on funding from top US and European VCs.
Hoxton Ventures is a European venture capital firm with a Silicon Valley mindset that invests early in founders building companies in new, non-obvious market categories, encouraging them to tackle the US market early.